Johnson & Johnson, employing approximately 110,300 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887. 

Fondé en 1887, Johnson & Johnson est l'un des premiers groupes pharmaceutiques mondiaux. 
- produits pharmaceutiques . Johnson & Johnson développe et commercialise des médicaments destinés au traitement des pathologies suivantes : maladies cardio-vasculaires, oncologie, maladies gastro-intestinales, immunologie, neurologie, dermatologie, contraception ...
- produits professionnels . J&J développe, fabrique et commercialise des produits et équipements médicaux destinés aux professionnels de la santé : systèmes de diagnostics, produits orthopédiques, produits de gynécologie, matériel chirurgical, ...
 -produits de grande consommation  : médicaments OTC, nutrition, soins de la personne (marques RoC, Neutrogena, etc.), ophtalmologie (1er producteur mondial de lentilles de contacts avec la marque Acuvue), hygiène féminine, soins bébé, ...

http://www.jnj.com

Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol (NUCYNTA® /PALEXIA® /PALEXIS®) 
Beerse, Belgium (June 7, 2010) -- Janssen Pharmaceutica N.V. (Janssen) announced today that it has expanded its licensing agreement with the Grünenthal Group (Grünenthal) to register, manufacture and commercialize Tapentadol in additional regions, including selected Asia Pacific, Latin American, African, and New European countries including Turkey and Greece, under Grünenthal's NUCYNTA® /PALEXIA® /PALEXIS® trademark for both the immediate- and prolonged-release (IR and PR) formulations.
 

Johnson & Johnson Reports 2010 First-Quarter Results: 
--Sales of $15.6 Billion Increased 4.0% Versus 2009 First Quarter; EPS was $1.62 --Excluding Special Items, 2010 First-Quarter EPS was $1.29, an increase of 2.4%*
NEW BRUNSWICK, N.J., April 20, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%. Domestic sales declined 5.0%, while international sales increased 14.4%, reflecting operational growth of 5.5% and a positive currency impact of 8.9%. 
Net earnings and diluted earnings per share for the first quarter of 2010 were $4.5 billion and $1.62, respectively. First-quarter 2010 net earnings included an after-tax gain of $910 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.6 billion and diluted earnings per share were $1.29, representing increases of 3.1% and 2.4%, respectively, as compared to the same period in 2009.* The Company updated its earnings guidance for full-year 2010 to $4.80 - $4.90 per share to reflect recent changes in foreign currency exchange rates. Earnings guidance excludes the impact of special items and now incorporates the impact of recently enacted health care reform legislation. 
"Thanks to the outstanding efforts of our people, we were able to deliver solid financial results," said William C. Weldon, Chairman and Chief Executive Officer. "This was accomplished despite a major product recall and the continued impact of patent expirations. We are well positioned for future growth." 
Worldwide Consumer sales of $3.8 billion for the first quarter represented an increase of 1.5% versus the prior year consisting of a decrease of 3.7% operationally and a positive impact from currency of 5.2%. Domestic sales decreased 9.6%; international sales increased 11.1%, which reflected an operational increase of 1.4% and a positive currency impact of 9.7%. 
Positive contributors to operational results were NEUTROGENA(R), AVEENO(R) and LE PETIT MARSEILLAIS(R) skin care products; ZYRTEC(R) over-the-counter allergy treatment; international sales of LISTERINE(R) antiseptic mouthrinse; and women's sanitary protection products. These operational sales increases were more than offset by the impact of the previously announced recall of selected OTC products as well as the devaluation of the Venezuelan currency. 
Worldwide Pharmaceutical sales of $5.6 billion for the first quarter represented a decrease of 2.5% versus the prior year consisting of an operational decline of 5.7% and a positive impact from currency of 3.2%. Domestic sales decreased 12.7%; international sales increased 15.5%, which reflected an operational increase of 6.6% and a positive currency impact of 8.9%. 
Products with strong operational growth included REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; and international sales of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication. Strong growth was also achieved from newly launched products including STELARA(TM) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; and SIMPONI(TM) (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. 
Sales results of TOPAMAX(R) (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL(R) (risperidone), an antipsychotic medication, were negatively impacted by generic competition. 
Worldwide Medical Devices and Diagnostics sales of $6.2 billion for the first quarter represented an increase of 12.5% versus the prior year consisting of an operational increase of 8.1% and a positive currency impact of 4.4%. Domestic sales increased 8.8%; international sales increased 15.9%, which reflected an operational increase of 7.5% and a positive currency impact of 8.4%. 
Primary contributors to operational growth included Ethicon's surgical care products; DePuy's orthopaedic joint reconstruction and sports medicine businesses; Ethicon Endo-Surgery's minimally invasive products and Advanced Sterilization Products' infection prevention solutions; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market. 
During the quarter, the Company filed for CE Mark in Europe for its NEVO(R) Sirolimus-Eluting Coronary Stent, the first drug-eluting stent to utilize RES TECHNOLOGY(TM) , eliminating the need for surface coated and permanent polymers. 
 

Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results: 
--2009 Fourth-Quarter Sales of $16.6 Billion increased 9.0%; EPS was $0.79 --2009 Full-Year Sales of $61.9 Billion decreased 2.9%; Full-Year EPS was $4.40 --Excluding Special Items, 2009 Fourth-Quarter EPS was $1.02, an increase of 8.5% --And 2009 Full-Year EPS was $4.63, an increase of 1.8%*
NEW BRUNSWICK, N.J., Jan 26, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson today announced sales of $16.6 billion for the fourth quarter of 2009, an increase of 9.0% as compared to the fourth quarter of 2008. Operational growth was 4.5% and currency contributed 4.5%. Domestic sales were up 2.6%, while international sales increased 15.6%, reflecting operational growth of 6.4% and a positive currency impact of 9.2%. Worldwide sales for the full-year 2009 were $61.9 billion, a decrease of 2.9% over 2008. Operational results declined 0.3% and the negative impact of currency was 2.6%. Domestic sales declined 4.4%, while international sales declined 1.4%, reflecting operational growth of 3.9% and a negative currency impact of 5.3%. 
Net earnings and diluted earnings per share for the fourth quarter of 2009 were $2.2 billion and $0.79 respectively. Fourth quarter 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation matters. Fourth quarter 2008 net earnings included special items related to in-process research and development charges of $141 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation matters. Excluding these special items, net earnings for the current quarter were $2.8 billion and diluted earnings per share were $1.02, representing increases of 8.4% and 8.5%, respectively, as compared to the same period in 2008.* 
Net earnings and diluted earnings per share for the full-year 2009 were $12.3 billion and $4.40. Full-year 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation matters. Full-year 2008 net earnings included special items related to in-process research and development charges of $181 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation matters. Excluding these special items, net earnings for the full-year 2009 were $12.9 billion. Diluted earnings per share for the full-year 2009 were $4.63, representing an increase of 1.8%, as compared with the full-year in 2008.* 
The Company announced earnings guidance for full-year 2010 of $4.85 to $4.95 per share, which excludes the impact of special items. 
"In a year of tremendous challenge, we maintained our long-term focus while delivering solid results -- a great tribute to the employees of Johnson & Johnson," said William C. Weldon, Chairman and Chief Executive Officer. "We made important investments in acquisitions, strategic partnerships and launches of recently-approved innovative products while preserving our financial flexibility to continue to invest in innovation. This positions us well for continued leadership and growth in global health care as we enter 2010." 
Worldwide Consumer sales of $15.8 billion for the full-year 2009 represented a decrease of 1.6% over the prior year with operational growth of 2.0% and a negative currency impact of 3.6%. Domestic sales decreased 1.4%; international sales decreased 1.7%, which reflected operational growth of 4.7% and a negative currency impact of 6.4%. 
Primary contributors to operational growth included NEUTROGENA(R), AVEENO(R) and the Dabao skin care products; international sales of LISTERINE(R) antiseptic mouthrinse; SPLENDA(R) No Calorie Sweetener; and sales from the acquisition of Vania Expansion SNC. Sales growth was negatively impacted due to the initial build of inventory by the trade related to the 2008 launch of Zyrtec. 
Worldwide Pharmaceutical sales of $22.5 billion for the full-year 2009 represented a decrease of 8.3% versus the prior year with an operational decline of 6.1% and a negative impact from currency of 2.2%. Domestic sales decreased 12.1%; international sales decreased 2.6%, which reflected an operational increase of 3.0% and a negative currency impact of 5.6%. 
 

Johnson & Johnson Reports 2009 Third-Quarter Results: 
Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
EPS of $1.20 increased 2.6% Versus 2008 Third Quarter
NEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%. 
Net earnings and diluted earnings per share for the third quarter of 2009 were $3.3 billion and $1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008. The Company raised its earnings guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes the impact of special items. 
"We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth." 
Worldwide Consumer sales of $4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%. 
Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO(R) skin care products; SPLENDA(R) No Calorie Sweetener; Le Petit Marseillais(R) beauty care products; and LISTERINE(R) antiseptic mouthrinse. Other growth drivers were sales from the acquisition of Vania Expansion SNC. 
Worldwide Pharmaceutical sales of $5.3 billion for the third quarter represented a decrease of 14.1% versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%. 
REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; and RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX(R) (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL(R) (risperidone), an antipsychotic medication, were negatively impacted by generic competition. ...

Johnson & Johnson Reports 2009 Second-Quarter Results:
See text copy below:
Johnson & Johnson Reports 2009 Second-Quarter Results:
--Sales of $15.2 Billion Decreased 7.4% Versus 2008 Second Quarter --EPS of $1.15 Decreased 2.5%* Versus 2008 Second Quarter, Excluding 2008 Special Items
NEW BRUNSWICK, N.J., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --  Johnson & Johnson (NYSE: JNJ) today announced sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%.  Domestic sales declined 6.7%, while international sales declined 8.0%, reflecting operational growth of 3.9% and a negative currency impact of 11.9%.
Net earnings and diluted earnings per share for the second quarter of 2009 were $3.2 billion and $1.15, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of $40 million. Excluding this charge, net earnings for the quarter and diluted earnings per share represent decreases of 4.7% and 2.5%, respectively, as compared to the same period in 2008.* The Company confirmed its earnings guidance for full-year 2009 of $4.45 - $4.55 per share, which excludes the  impact of special items.
"I am proud of the accomplishments of our people in continuing to deliver very solid operational results in light of the significant impacts of patent expirations and the economic environment," said William C. Weldon, Chairman and Chief Executive Officer.  "Our investments through internal research and development, strategic partnerships and acquisitions have allowed us to build what is considered by many to be one of the best pipelines in our industry.  We will continue to invest in our portfolio of innovative products to meet the needs of patients and consumers around the world."
Worldwide Consumer sales of $3.9 billion for the second quarter represented a decrease of 4.5% versus the prior year with an increase of 3.1% operationally and a negative impact from currency of 7.6%. Domestic sales increased 0.8%; while international sales decreased 8.4%, which reflected an operational increase of 4.7% and a negative currency impact of 13.1%.
LISTERINE(R) antiseptic mouthrinse and the skin care lines of NEUTROGENA(R) and AVEENO(R) contributed to operational sales growth during the quarter. Other growth drivers were sales from the recently completed acquisition of the French company Vania Expansion SNC.
Worldwide Pharmaceutical sales of $5.5 billion for the second quarter represented a decrease versus the prior year of 13.3% with an operational decline of 8.5% and a negative impact from currency of 4.8%. Domestic sales decreased 16.4%; while international sales decreased 8.7%, which reflected an operational increase of 3.3% and a negative currency impact of 12.0%.
REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; and CONCERTA(R) (methylphenidate HCI), a treatment for attention deficit hyperactivity disorder,  had strong operational sales performance during the quarter. Sales results of TOPAMAX(R) (topiramate), an anti-epileptic, and RISPERDAL(R) (risperidone), an antipsychotic medication, were negatively impacted by generic competition.
During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI(TM) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, active psoriatic arthritis with or without methotrexate, and active ankylosing spondylitis. The FDA also approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder. The Drug Enforcement Administration (DEA) issued their final ruling and placed NUCYNTA(TM) (tapentadol) CII immediate release tablets for the relief of moderate to severe acute pain in patients 18 years of age or older into Schedule II of the Controlled Substances Act. The product is now available to patients.
The Company also announced a definitive agreement to acquire Cougar Biotechnology, a development stage biopharmaceutical company with a specific focus on oncology, for approximately $1.0 billion in a cash tender offer.  On July 9, 2009, the acquisition of Cougar Biotechnology was completed.  On July 2, 2009, the Company announced a definitive agreement with Elan Corporation, plc. whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program and will invest $1 billion in Elan newly issued American Depositary Receipts (ADRs).
Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the second quarter represented a decrease of 3.1% versus the prior year with an operational increase of 2.9% and a negative currency impact of 6.0%. Domestic sales increased 1.9%; while international sales decreased 7.2%, which reflected an operational increase of 3.7% and a negative currency impact of 10.9%.
Primary contributors to the operational growth included Ethicon's surgical care products; Ortho-Clinical Diagnostics' professional products; Ethicon Endo-Surgery's minimally invasive products; and DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses. Also contributing to growth were sales of products acquired as part of the completed acquisition of Mentor Corporation, a leading supplier of medical products for the global aesthetic market. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market as well as the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

Johnson & Johnson has added a new press release to the Investor Relations section of the Company's Web site
NEW BRUNSWICK, N.J., July 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology. 
Johnson & Johnson's tender offer for shares of Cougar Biotechnology common stock expired at 5 p.m. Eastern Daylight Time (EDT) yesterday with approximately 20,148,930 shares tendered, representing approximately 95.9% of Cougar Biotechnology's outstanding common stock. The acquisition was completed yesterday through what is known as a "short-form" merger, without a vote or meeting of Cougar Biotechnology's remaining shareholders. 
Cougar Biotechnology currently is conducting two Phase III trials for abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer. The first Phase III trial is testing abiraterone acetate in patients with metastatic, castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy has failed. The second Phase III trial is studying abiraterone acetate in patients with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. 
One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 percent of cancer-related deaths in the United States. 
Cougar Biotechnology now operates as a wholly-owned subsidiary of Johnson & Johnson and will work with Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., a Johnson & Johnson company. 
"With the acquisition of Cougar Biotechnology and its talented team, we have strengthened our position in the global oncology market and our efforts to provide a meaningful difference in the lives of millions of patients worldwide," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, Ortho Biotech Oncology Research & Development. "Abiraterone acetate now becomes one of many new treatments we are developing, which we hope will change the course of cancer treatment by targeting cancer cells and the tumor microenvironment." 
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world